miR‑32‑5p suppresses the proliferation and migration of pancreatic adenocarcinoma cells by targeting TLDC1

Yuan,Peng; Tang,Chaofeng; Chen,Bendong; Lei,Peng; Song,Jianjun; Xin,Guojun; Wang,Zuozheng; Hui,Yongfeng; Yao,Weijie; Wang,Genwang; Zhao,Guozhong

doi:10.3892/mmr.2021.12392

miR‑32‑5p suppresses the proliferation and migration of pancreatic adenocarcinoma cells by targeting TLDC1

Authors:
- Peng Yuan
- Chaofeng Tang
- Bendong Chen
- Peng Lei
- Jianjun Song
- Guojun Xin
- Zuozheng Wang
- Yongfeng Hui
- Weijie Yao
- Genwang Wang
- Guozhong Zhao
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China, Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China, Department of Hepatobiliary Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China
Published online on: August 31, 2021 https://doi.org/10.3892/mmr.2021.12392
Article Number: 752
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic adenocarcinoma (PAAD) is one of the most fatal types of cancer in humans. However, the molecular mechanisms underlying the migration and invasion abilities of PAAD cells remain unclear. The aim of the present study was to explore the regulatory roles of microRNA (miR)‑32‑5p in PAAD cells. miR‑32‑5p mimic and inhibitor were used to transfect the human PAAD AsPC‑1 cell line to determine the role of miR‑32‑5p in cell proliferation and metastasis. The starBase database predicted the binding of miR‑32‑5p to the target gene TBC/LysM‑associated domain containing 1 (TLDC1). Further analyses were performed to assess miR‑32‑5p and TLDC1 expression levels in healthy and PAAD tissues, as well as the association between miR‑32‑5p or TLDC1 expression and the prognosis of patients with PAAD. The interaction between miR‑32‑5p and TLDC1 was verified using the dual‑luciferase reporter assay. miR‑32‑5p and TLDC1 expression levels were detected by reverse transcription‑quantitative PCR and western blotting, respectively. The Cell Counting Kit‑8 assay was utilised to assess cell proliferation, whereas the wound‑healing and Transwell assays were conducted to assess cell migration and invasion, respectively. miR‑32‑5p expression levels were markedly lower in PAAD tissue compared with those in healthy tissue, and were significantly lower in PAAD cell lines compared with those in the human pancreatic duct cell line HPDE6, which corresponded with poor prognosis. miR‑32‑5p significantly inhibited the proliferation of PAAD cells and markedly reduced migration and invasion compared with the negative controls. miR‑32‑5p was shown to target TLDC1, with miR‑32‑5p expression in PAAD being negatively correlated with TLDC1 expression. High TLDC1 expression levels were associated with a poorer prognosis compared with low TLDC1 expression levels. Co‑transfection of miR‑32‑5p mimic and pcDNA/TLDC1 demonstrated that TLDC1 significantly reversed miR‑32‑5p‑mediated inhibition of the proliferation, migration and invasion of PAAD cells. Overall, the present study demonstrated that miR‑32‑5p may serve as a tumor‑suppressor gene by inhibiting the proliferation and migration and invasion of PAAD cells via the downregulation of TLDC1. Therefore, miR‑32‑5p may serve as a potential diagnostic or prognostic marker for PAAD.

View Figures

View References

1	Xu B, Liu J, Xiang X, Liu S, Zhong P, Xie F, Mou T and Lai L: Expression of miRNA-143 in pancreatic cancer and its clinical significance. Cancer Biother Radiopharm. 33:373–379. 2018. View Article : Google Scholar : PubMed/NCBI
2	Yu Z, Zhao S, Wang L, Wang J and Zhou J: MiRNA-339-5p plays an important role in invasion and migration of pancreatic cancer cells. Med Sci Monit. 25:7509–7517. 2019. View Article : Google Scholar : PubMed/NCBI
3	Du W, Lei C, Wang Y, Ding Y and Tian P: LINC01232 sponges multiple miRNAs and its clinical significance in pancreatic adenocarcinoma diagnosis and prognosis. Technol Cancer Res Treat. 20:15330338209885252021. View Article : Google Scholar : PubMed/NCBI
4	Wang C, Huang Y, Zhang J and Fang Y: MiRNA-339-5p suppresses the malignant development of gastric cancer via targeting ALKBH1. Exp Mol Pathol. 115:1044492020. View Article : Google Scholar : PubMed/NCBI
5	Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V and Neesse A: Microenvironmental determinants of pancreatic cancer. Physiol Rev. 100:1707–1751. 2020. View Article : Google Scholar : PubMed/NCBI
6	Leinwand J and Miller G: Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol. 21:1152–1159. 2020. View Article : Google Scholar : PubMed/NCBI
7	Liang H, Tang Y, Zhang H and Zhang C: MiR-32-5p regulates radiosensitization, migration and invasion of colorectal cancer cells by targeting TOB1 gene. Onco Targets Ther. 12:9651–9661. 2019. View Article : Google Scholar : PubMed/NCBI
8	Du B, Zhang P, Tan Z and Xu J: MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother. 96:1246–1252. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zeng S, Liu S, Feng J, Gao J and Xue F: MicroRNA-32 promotes ovarian cancer cell proliferation and motility by targeting SMG1. Oncol Lett. 20:733–741. 2020. View Article : Google Scholar : PubMed/NCBI
10	Ye T, Zhang N, Wu W, Yang B, Wang J, Huang W and Tang D: SNHG14 promotes the tumorigenesis and metastasis of colorectal cancer through miR-32-5p/SKIL axis. In Vitro Cell Dev Biol Anim. 55:812–820. 2019. View Article : Google Scholar : PubMed/NCBI
11	Wang M, Sun Y, Xu J, Lu J, Wang K, Yang DR, Yang G, Li G and Chang C: Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. Int J Cancer. 143:100–112. 2018. View Article : Google Scholar : PubMed/NCBI
12	Liu YJ, Zhou HG, Chen LH, Qu DC, Wang CJ, Xia ZY and Zheng JH: MiR-32-5p regulates the proliferation and metastasis of cervical cancer cells by targeting HOXB8. Eur Rev Med Pharmacol Sci. 23:87–95. 2019.PubMed/NCBI
13	Nguyen JT, Ray C, Fox AL, Mendonça DB, Kim JK and Krebsbach PH: Mammalian EAK-7 activates alternative mTOR signaling to regulate cell proliferation and migration. Sci Adv. 4:eaao58382018. View Article : Google Scholar : PubMed/NCBI
14	Nagase T, Kikuno R, Nakayama M, Hirosawa M and Ohara O: Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 7:273–281. 2000. View Article : Google Scholar : PubMed/NCBI
15	Schröder B, Wrocklage C, Pan C, Jäger R, Kösters B, Schäfer H, Elsässer HP, Mann M and Hasilik A: Integral and associated lysosomal membrane proteins. Traffic. 8:1676–1686. 2007. View Article : Google Scholar : PubMed/NCBI
16	Nguyen JT, Haidar FS, Fox AL, Ray C, Mendonça DB, Kim JK and Krebsbach PH: mEAK-7 forms an alternative mTOR complex with DNA-PKcs in human cancer. iScience. 17:190–207. 2019. View Article : Google Scholar : PubMed/NCBI
17	Riou P, Saffroy R, Comoy J, Gross-Goupil M, Thiéry JP, Emile JF, Azoulay D, Piatier-Tonneau D, Lemoine A and Debuire B: Investigation in liver tissues and cell lines of the transcription of 13 genes mapping to the 16q24 region that are frequently deleted in hepatocellular carcinoma. Clin Cancer Res. 8:3178–3186. 2002.PubMed/NCBI
18	Ellsworth RE, Field LA, Love B, Kane JL, Hooke JA and Shriver CD: Differential gene expression in primary breast tumors associated with lymph node metastasis. Int J Breast Cancer. 2011:1427632011. View Article : Google Scholar : PubMed/NCBI
19	Mendonça DB, Nguyen JT, Haidar F, Fox AL, Ray C, Amatullah H, Liu F, Kim JK and Krebsbach PH: MicroRNA-1911-3p targets mEAK-7 to suppress mTOR signaling in human lung cancer cells. Heliyon. 6:e057342020. View Article : Google Scholar : PubMed/NCBI
20	Gao ZQ, Wang JF, Chen DH, Ma XS, Wu Y, Tang Z and Dang XW: Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci. 7:662017. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
23	Cao J, Yang J, Ramachandran V, Arumugam T, Deng DF, Li ZS, Xu LM and Logsdon CD: TM4SF1 regulates pancreatic cancer migration and invasion in vitro and in vivo. Cell Physiol Biochem. 39:740–750. 2016. View Article : Google Scholar : PubMed/NCBI
24	Xu Q, Zong L, Chen X, Jiang Z, Nan L, Li J, Duan W, Lei J, Zhang L, Ma J, et al: Resveratrol in the treatment of pancreatic cancer. Ann N Y Acad Sci. 1348:10–19. 2015. View Article : Google Scholar : PubMed/NCBI
25	Cao L, Chen X, Xiao X, Ma Q and Li W: Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways. Int J Oncol. 49:735–743. 2016. View Article : Google Scholar : PubMed/NCBI
26	Koay EJ, Amer AM, Baio FE, Ondari AO and Fleming JB: Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers. Cancer Lett. 381:237–243. 2016. View Article : Google Scholar : PubMed/NCBI
27	Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A and Cervantes A: Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev. 68:124–135. 2018. View Article : Google Scholar : PubMed/NCBI
28	Hartwig W, Werner J, Jäger D, Debus J and Büchler MW: Improvement of surgical results for pancreatic cancer. Lancet Oncol. 14:e476–e485. 2013. View Article : Google Scholar : PubMed/NCBI
29	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
30	Qian B, Wei L, Yang Z, He Q, Chen H, Wang A, Yang D, Li Q, Li J, Zheng S and Fu W: Hic-5 in pancreatic stellate cells affects proliferation, apoptosis, migration, invasion of pancreatic cancer cells and postoperative survival time of pancreatic cancer. Biomed Pharmacother. 121:1093552020. View Article : Google Scholar : PubMed/NCBI
31	Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, et al: Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): A prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncol. 18:486–499. 2017. View Article : Google Scholar : PubMed/NCBI
32	Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, Andrén-Sandberg A, Asbun HJ, Bassi C, Bockhorn M, et al: Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 156:1–14. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L and Pei H: miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother. 96:1341–1348. 2017. View Article : Google Scholar : PubMed/NCBI
34	Daniel R, Wu Q, Williams V, Clark G, Guruli G and Zehner Z: A Panel of MicroRNAs as diagnostic biomarkers for the identification of prostate cancer. Int J Mol Sci. 18:12812017. View Article : Google Scholar : PubMed/NCBI
35	Wang R, Huang Z, Qian C, Wang M, Zheng Y, Jiang R and Yu C: LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis. Biochem Biophys Res Commun. 526:1005–1012. 2020. View Article : Google Scholar : PubMed/NCBI
36	Cao XM: Role of miR-337-3p and its target Rap1A in modulating proliferation, invasion, migration and apoptosis of cervical cancer cells. Cancer Biomark. 24:257–267. 2019. View Article : Google Scholar : PubMed/NCBI
37	Ji H, Sang M, Liu F, Ai N and Geng C: MiR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer. Pathol Res Pract. 215:697–704. 2019. View Article : Google Scholar : PubMed/NCBI
38	Liu J, Bian T, Feng J, Qian L, Zhang J, Jiang D, Zhang Q, Li X, Liu Y and Shi J: MiR-335 inhibited cell proliferation of lung cancer cells by target Tra2β. Cancer Sci. 109:289–296. 2018. View Article : Google Scholar : PubMed/NCBI
39	Cannell IG, Kong YW and Bushell M: How do microRNAs regulate gene expression? Biochem Soc Trans. 36((Pt 6)): 1224–1231. 2008. View Article : Google Scholar : PubMed/NCBI